From Needle to Pill: The UK's Weight Loss Revolution
From Needle to Pill: The UK's Weight Loss Revolution
Between May and June 2026, Chemist4U surveyed more than 3,500 UK adults to better understand how people currently feel about weight loss, GLP-1 injections and the arrival of weight loss tablets.
Participants included people who go to the gym, walk regularly, play sports, have used or are currently using weight loss injections, have tried to lose weight, or have never engaged with any of the above.
The research was designed to build a broad picture of public attitudes towards weight loss treatment, including perceptions around injections, tablets, needles, convenience, effectiveness and confidence in using GLP-1 medications.
GLP-1 medications have already transformed the treatment of weight loss, with an estimated two million UK adults now using them. But while demand for the likes of Wegovy® and Mounjaro® continues to grow, injections still put some people off.
That could be about to change.
Weight loss tablets are expected to be a game changer, making GLP-1 treatments feel more accessible for a whole new group of people, especially those who don’t like needles, or don’t want to inject themselves every week.
All the early signs point to this paradigm shift. In the US, oral semaglutide (Wegovy® pill) launched in January 2026 and saw record-breaking prescription demand within weeks. The UK market is expected to follow closely behind.
This report explores how attitudes towards GLP-1 treatments are changing as tablets arrive in the UK. By talking to patients, prospective patients and the wider public, we uncover what is driving excitement, where people still have concerns, and why tablets could encourage many more people to consider treatment for the first time.
Key findings at a glance
For many people, injections are still the biggest barrier: A large number of eligible UK adults say they have avoided GLP-1 treatments because they do not want to inject themselves. Tablets could open the door to people who previously ruled treatment out entirely.
People are interested in pills, but still have questions: Before learning more about the treatments, most non-users said they would prefer a tablet over an injection. But interest alone is not enough to guarantee people will start treatment.
Clear education will matter: Many people are still unsure how effective weight loss tablets are, how they work, and what taking them involves. Helping people understand what to expect will be key to building confidence and long-term use.
The results are clinically significant: Oral GLP-1 treatments are already delivering strong weight loss results in clinical trials. Oral semaglutide 25mg achieved average weight loss of 16.6% at 64 weeks, while orforglipron 36mg achieved 12.4% at 72 weeks.
The UK market is approaching a major shift: The focus is no longer on whether they’re coming, but how patients, healthcare providers and the wider public respond when they arrive.
“Weight loss tablets are not about replacing healthy habits or offering a shortcut. They’re about giving a wider group of people access to a clinically proven treatment in a way that feels more manageable, more familiar and more realistic for everyday life. For many patients, the needle has been the thing holding them back. Tablets could change that, but only if they are introduced responsibly, with the right education, support and expectations in place.”
GLP-1 injections have revolutionised weight loss, allowing those facing obesity and other weight-related conditions to take a meaningful step towards a healthier life. Yet at the same time, the injections themselves are still a major reason others have not started their journey.
For some, it’s a fear of needles. For others, it’s the idea of injecting themselves every week. Or storing treatment in the fridge. Or simply feeling that injections aren’t compatible with their day-to-day life. Even people who could medically benefit from treatment often say the injection itself is the thing holding them back from getting the help they need.
This means some of the most effective weight loss treatments available today are still out of reach for people who feel uncomfortable with how they’re taken.
For years, this has left a large group of potential patients sitting on the sidelines. The arrival of weight loss tablets could begin to change that.
The facts
1 in 10 people dislike needles, but would still consider them for weight loss
Around 10% of respondents said they dislike injections or needles, but would still be willing to use them for weight loss purposes.
This highlights just how strong demand for effective weight loss treatment has become. Many people are willing to push past discomfort if they believe the treatment will help them achieve meaningful results.
Younger adults are the most likely to have a fear of needles
18-24 year olds were the most likely age group to report a significant fear or phobia of needles, at 15.49%.
This shows that a significant portion of the UK’s nearly 6 million younger adults may be interested in weight loss support but are put off treatment by anxiety around injections.
Oral treatments could help bring younger patients into the category who may never have considered injections.
Older adults are the most comfortable with injections
Adults aged 55+ were the most likely to say they are comfortable with needles and injections, with 43.75% reporting no concerns.
This may be due to the fact that older adults may already feel more familiar with injections through previous medical treatments and healthcare experiences.
Women are more willing to tolerate injections for weight loss
Women were more likely than men to say they would tolerate injections for weight loss despite disliking needles, at 11.23% compared to 7.94%.
This could mean men who are hesitant about injections may represent a significant opportunity for oral GLP-1 treatments.
Attitudes towards injections vary across the UK
Attitudes towards injections differed noticeably depending on location.
Respondents in Birmingham (10.92%), Glasgow (10.74%) and Manchester (10.51%) were the most likely to report a significant fear or phobia of needles.
Meanwhile, people in Brighton (14.17%), Nottingham (12.63%) and Liverpool (12.03%) were the most likely to say they dislike injections, but would still be willing to use them for weight loss purposes.
These findings suggest attitudes towards injections are not consistent across the UK.
In some cities, needle anxiety remains a clear barrier to treatment adoption, particularly in areas where fear or phobia rates are highest.
In other locations, people appear more willing to tolerate injections if they believe the treatment will deliver meaningful weight loss results.
Oral weight loss treatments could help reduce hesitation in areas where needle fear is more common, while also appealing to people who are already motivated to seek treatment, but would prefer a more familiar and convenient format.
Even current GLP-1 users often dislike injections
17.65% of people currently using GLP-1 injections said they dislike needles or injections, but tolerate them because of the results.
Even existing users do not always see injections as convenient or desirable. Many are simply willing to compromise because the treatment works.
Oral GLP-1s may not only appeal to new patients, but to existing users looking for something more comfortable and convenient.
Fear of needles is stopping some people from starting treatment
13% of people who had considered using GLP-1s but decided against it said a significant fear of needles influenced their decision.
This shows that for a meaningful number of people, the injection itself is enough to stop them from accessing treatment entirely.
The arrival of tablets could encourage entirely new groups of patients to consider GLP-1 treatment for the first time.
Many people would trade some efficacy to avoid injections
On average, respondents said they would accept up to a 9.11% reduction in efficacy to avoid injections.
However, 21.97% said no reduction in effectiveness would be acceptable, and tablets would need to work equally as well as injections.
Convenience matters, but people still expect strong clinical results from oral GLP-1s.
The bottom line
“Weight loss tablets could change far more than how GLP-1 treatments are taken. They could change who feels comfortable accessing them in the first place. For millions of people put off by injections, tablets may finally make clinically proven weight loss treatment feel like a realistic option.”
James O’Loan, CEO and Prescribing Pharmacist at Chemist4U
Beyond needles: what’s stopping uptake?
While needles remain an important barrier for some, our research shows they’re far from the only reason people aren’t using GLP-1 treatments. Concerns around side effects, long-term safety, cost and whether medication feels necessary in the first place all play their part in informing how people feel about starting weight loss treatments.
As tablets arrive in the UK, they may help remove one barrier, but wider education, reassurance and accessibility will still play a major role in uptake.
Side effects are the biggest concern
Among people who have never used GLP-1 injections, side effects were the most commonly selected reason for not pursuing treatment, with almost a quarter of people we spoke to (24.45%) saying they put them off.
Women were significantly more likely than men to worry about side effects, with 29.10% citing this concern compared to 19.59% of men.
For many people, concerns about nausea, digestive symptoms and other potential side effects are still creating hesitation around treatment.
As oral GLP-1s launch, clear education around side effects, expectations and ongoing support will be essential to building confidence.
Many people still prefer a diet and exercise-first approach
Nearly a quarter (24.41%) of respondents said they preferred to focus on changes to their diet and levels of exercise rather than starting medication. Adults aged 55+ were the most likely age group to feel this way, despite – or perhaps because of – a greater likelihood of being on medication already.
Some people still see weight loss medication as a last resort, rather than part of a wider weight management approach.
Tablets may feel more approachable and familiar than injections, but public understanding around how GLP-1s fit alongside healthy lifestyle changes will still matter.
“Weight loss medication is not there to replace healthy habits. It’s there to support them. For many people, these treatments can make it easier to build routines around nutrition, movement and consistency by helping reduce hunger, cravings and food noise. The medication supports that process, but long-term success still comes from the habits people build alongside it.”
More than one in five (23.01%) respondents said concerns about long-term safety or usage stopped them from pursuing GLP-1 treatments.
However, the new oral GLP-1 treatments contain the same active ingredients already used in existing injectable medications, which have undergone extensive clinical testing and have been used in diabetes treatment for years.
As tablets become more widely available, clearer communication around existing safety data, long-term research and the history of GLP-1 use in diabetes care could help reassure patients and improve confidence in treatment.
This is where providers need to step in and make sure there’s expert, easy to digest guidance for existing customers and potential patients alike. Whether someone is switching treatments or completely new to GLP-1s, confidence comes from education.
Before and after using needles: how our patients’ views changed
Much of the conversation around GLP-1 treatments focuses on the fear of needles before treatment begins. But our research suggests perceptions can shift significantly once people actually start using injections.
Most users were concerned before starting injections, but most feel better after using them.
Among current and previous GLP-1 users, 60.84% said they were concerned about injecting themselves before starting treatment, including 20.89% who said they were very concerned.
However, after using GLP-1 injections, more than two thirds (70.23%) said they now feel better about injections overall. And more than a third (37.86%) said they feel much better.
The findings suggest that the reality of using GLP-1 injections is often less intimidating than many people initially expect.
Fear and hesitation around injections is extremely common, even among people who ultimately decide to start treatment.
Weight loss tablets could help remove a major psychological barrier for people who are interested in treatment but feel intimidated by injections.
While tablets may help more people start treatment, the findings also suggest that fear of injections can often reduce over time once people become familiar with the process.
Younger adults were the most anxious about injections
18-24 year olds were the most likely age group to say they were concerned before starting injections, with 76.47% reporting concern.
Current users were slightly more concerned than previous users
63.14% of current GLP-1 users said they were concerned before starting injections, compared to 56.25% of previous users.
Many people continue with treatment despite initially feeling anxious or uncomfortable about injections.
Tablets may help encourage people who are currently hesitating to take that first step into treatment.
“Fear around injections is incredibly common before starting GLP-1 treatments, and our research clearly shows that. But what is striking is how often those fears reduce once people actually begin treatment. For many patients, the anticipation is worse than the reality. While that doesn’t mean injections are the right choice for everyone, it does highlight the importance of education, reassurance and giving patients options that feel manageable for them.”
While oral GLP-1 treatments could change the face of weight loss, are the public aware of this shift? And once people learn these tablets are coming, how much interest is really there?
Is Britain ready?
As weight loss tablets move closer to launch, we wanted to understand how aware people already are of this new option. We asked respondents whether they knew that a tablet version of Wegovy® is expected to become available in the UK in 2026.
Awareness of the Wegovy® pill remains relatively low
Despite growing media attention around weight loss tablets, just 18.35% of respondents said they were aware that a tablet version of Wegovy® is expected to become available in the UK in 2026. More than 4 in 5 people (81.65%) said they were not aware.
Younger adults were the most aware
Adults aged 18-24 reported the highest awareness levels, with more than a quarter (25.92%) saying they knew about the upcoming launch. Awareness steadily declined with age, falling to just 9.97% among adults aged 55+.
Younger adults appear more engaged with emerging conversations around GLP-1 treatments and weight loss innovation, while older adults remain significantly less aware of the shift towards tablets.
Engaging with GLP-1 users on platforms like TikTok and Instagram likely helps increase treatment awareness among younger adults, while also providing a positive example of what their own journey could look like.
Patient education may need to focus more heavily on older age groups.
People already engaged in weight loss were far more aware
Among people who currently use or previously used weight loss injections, 37.20% were aware of the pill. Awareness was also much higher among people who had tried to lose weight or were actively trying to lose weight (18.96%) compared to people with no interest in changing their weight (8.55%).
Gym-goers also reported relatively high awareness at 28.05%.
People already engaged in weight loss, fitness or GLP-1 treatment conversations are significantly more likely to know about upcoming oral treatments.
Early demand for oral GLP-1s is likely to come from people already familiar with weight loss treatments, before awareness spreads more widely into the general public.
The challenge for oral GLP-1s will not just be meeting demand from existing interest groups, but expanding awareness to the much larger population who still know very little about these treatments.
“Awareness of weight loss tablets is still relatively low among the wider public, but interest is likely to grow quickly as these treatments become available in the UK. What stands out from the research is that awareness is currently highest among people already engaged in weight loss or GLP-1 treatment conversations. As tablets arrive, there will be a real need for clear, balanced education so people understand what these treatments are, how they work, and whether they are right for them.”
James O’Loan, CEO and Prescribing Pharmacist at Chemist4U
How we feel about tablets
How people feel about a treatment matters. Public perception can shape everything from interest and confidence to long-term uptake and engagement. As oral GLP-1 treatments move closer to the UK market, understanding how people emotionally respond to the idea of a weight loss tablet could offer an early indication of how these treatments may be adopted once they become available.
To explore this, we asked respondents which statements best reflected how they feel about weight loss tablets compared to injections.
Tablets are seen as more convenient
More than a third (35.50%) of respondents said weight loss tablets would feel more convenient and easier to fit into daily life.
People aged 45-54 were the most likely to agree with this statement, at 37.46%.
42.35% of current GLP-1 injection users also said tablets would feel more convenient, rising to 55.47% among people who had previously used GLP-1 injections. It may even be this lack of convenience that caused these users to stop their treatment in the first place.
Convenience is one of the biggest perceived advantages of oral GLP-1s, including among people who already have experience using injections. Tablets may appeal not just to new patients, but also to existing or previous injection users looking for a treatment option that feels easier to maintain.
Many people believe tablets could increase uptake
33.63% of respondents said more people would be likely to take weight loss medication if it was available in tablet form.
People aged 35-44 were the most likely to agree.
A significant proportion of the public already believes tablets could encourage more people to consider treatment.
Oral GLP-1s may help expand the category beyond current injection users and reach people who previously felt hesitant about treatment.
Tablets feel more approachable to many people
30.76% of respondents said tablets would feel more approachable than injections.
Adults aged 45-54 were the most likely to feel this way.
For many people, tablets feel less intimidating and more familiar than self-injecting medication.
The format itself may help reduce psychological barriers around starting treatment.
Tablets could make weight loss treatment feel more mainstream
30.17% of respondents said tablets would make prescription weight loss treatment feel more ‘normal’ or mainstream.
People aged 45-54 were the most likely to agree with this statement
Tablets may help shift public perceptions of weight loss medication away from something viewed as highly medical or specialist, to something more commonplace.
As oral GLP-1s become more visible, they could help normalise prescription weight loss treatment among the wider public.
Some people still see injections as more serious
More than a quarter (25.66%) of respondents said weight loss injections feel more serious and better suited to people with significant weight issues.
Adults aged 35-44 were the most likely to agree
Despite growing interest in tablets, some people still associate injections with stronger or more clinically significant treatment. Oral GLP-1s may still need to overcome perceptions that tablets are less effective or less medically credible than injections.
Daily tablets are seen as easier to remember
25.38% of respondents said taking a daily tablet would feel easier to remember than a weekly injection.
Adults aged 35-44 were the most likely to agree
For some people, building treatment into a daily routine may feel simpler than remembering a weekly injection schedule. The familiarity of taking a daily tablet could help some patients feel more comfortable starting and maintaining treatment long term.
“Weight loss treatment is not something most people use for a few days or weeks. For many patients, it can be months or even years of ongoing treatment, which means comfort, convenience and confidence really matter. Some people will still prefer injections, but for others, tablets may feel easier to fit into everyday life and more realistic to maintain long term. Giving patients options is incredibly important.”
While injections are still seen by some people as more ‘serious’ or clinically powerful, tablets are generally viewed as more appealing, approachable and easier to trust among the wider public, especially for people who have never used GLP-1 treatments before.
People are more likely to instinctively trust tablets
35.11% of respondents said they would instinctively trust tablets more for weight loss treatment, compared to 26.06% who said they would trust injections more.
For many people, tablets still feel more familiar, mainstream and easier to understand than injectable medication.
Current GLP-1 users still trust injections most
Current GLP-1 users still trust injections most, with 64.31% saying they trust injections more, compared to 30.98% who trust tablets more. Previous GLP-1 users were far more divided, with 52.34% trusting injections more and 43.75% trusting tablets more, suggesting confidence in tablets may grow once people move away from injectable treatment.
People who have never used GLP-1s were significantly more likely to instinctively trust tablets over injections, likely because pills feel more familiar, less intimidating and easier to fit into everyday life.
Nearly half of respondents said tablets feel more appealing
Almost half (48.27%) of respondents said a daily weight loss tablet feels more appealing overall than a weekly injection, with 21.61% saying tablets feel much more appealing.
There is already strong public interest in oral weight loss treatment before these medications have even officially launched in the UK.
The early demand for oral GLP-1s could be significant once awareness grows further.
Adults aged 25-34 were the most positive about tablets
Adults between 25 and 34 were the most likely age group to say tablets feel more appealing than injections. Meanwhile, adults aged 55+ were the most likely to say tablets feel less appealing.
Obesity rates in the UK have risen steadily for decades, with around two thirds of adults now overweight or obese. Our research suggests younger adults could become the driving force behind the next phase of obesity treatment adoption.
Adults aged 25-34 appear particularly open to oral GLP-1s, potentially making them the generation that accelerates the mainstream adoption of weight loss pills in the UK.
Younger adults may be more comfortable with convenience-led healthcare, digital prescribing and treatments that fit more naturally into everyday life, helping tablets feel more approachable than injections.
Older adults may still feel more comfortable sticking with existing injection formats, suggesting oral GLP-1 adoption could initially skew younger before expanding more broadly across older age groups over time.
Even injection users find tablets appealing
More than two thirds (71.88%) of previous GLP-1 injection users said a daily tablet feels more appealing than a weekly injection, while 66.67% of current injection users agreed, showing strong interest in oral options even among experienced users.
The appeal is even stronger among people who considered GLP-1s but never started. 65.07% of people who decided against injections said a daily tablet feels more appealing, alongside 64.25% of people who had only briefly considered treatment. Even among people who had never considered GLP-1 treatment before, 39.60% said tablets feel more appealing than injections.
The real question: would people actually seek a prescription?
Interest in weight loss tablets is one thing, but real-world uptake is another. To understand whether tablets could genuinely encourage more people to consider treatment, we asked respondents how likely they would be to seek a GLP-1 prescription within the next 12 months if the medication was available in tablet form instead of an injection.
More than a third said they would likely seek treatment
36.98% of respondents said they would be likely to seek a prescription for a GLP-1 tablet within the next 12 months, while 15.59% said they would be very likely.
25-34 year olds were the most likely age group to say they would seek a prescription for a GLP-1 tablet, with 54.23% saying they would be likely to do so.
There is already meaningful interest in oral GLP-1 treatment before these medications have fully launched in the UK. As awareness grows and tablets become available, demand for prescriptions could increase significantly, and providers need to be ready to support patients new and old with the right guidance and care.
Existing and previous GLP-1 users showed the highest intent
88.27% of current GLP-1 users said they would be likely to seek a prescription for a tablet version.
89.84% of previous GLP-1 users also said they would likely seek treatment.
Tablets could encourage hesitant patients to reconsider
65.30% of people who had considered GLP-1 injections but decided against them said they would likely seek a prescription if treatment was available as a tablet.
56.09% of people who had only briefly considered GLP-1s also said they would likely seek treatment.
The format of treatment alone appears capable of changing how many people feel about pursuing weight loss medication.
Efficacy: the biggest uncertainty
One of the biggest unanswered questions around oral GLP-1s is not convenience or appeal, but effectiveness. While many people like the idea of a tablet, confidence still depends on whether patients believe pills can deliver results comparable to injections.
To explore this, we asked respondents how effective they believe weight loss tablets would be compared to injections, alongside how much of a reduction in effectiveness they would personally accept in exchange for avoiding injections.
Most people believe tablets could match injections
More than half (51.65%) of respondents believe tablets would be either equally as effective or more effective than injections, including nearly a third (32.77%) who believe they would work equally as well.
Confidence in oral GLP-1s already appears relatively strong, despite tablets not yet being widely available in the UK.
Some people still see injections as stronger
17.18% believe tablets would be less effective than injections, particularly among existing and previous GLP-1 injection users.
People already seeing results from injections appear more likely to trust the treatment format they already know.
“Many people instinctively see injections as the ‘stronger’ or more serious treatment, particularly if they are already getting good results from them. That does not necessarily mean tablets are ineffective. Often, it reflects how we psychologically associate injections with more intensive medical care. As oral GLP-1s become more established and more people see real-world results from them, confidence in tablet formats is likely to grow.”
January 2026 marked the start of a new chapter for weight loss treatment. The FDA approved oral semaglutide 25mg, also known as the Wegovy® pill, making it the first GLP-1 tablet approved specifically for obesity. Soon after came Eli Lilly’s orforglipron (Foundayo®), another daily pill designed for weight management. Now, attention is turning to the UK. The tablet era of weight loss treatment is on its way.
Pill vs injection: side by side
“There is no single ‘best’ option when it comes to GLP-1 treatments. For some people, tablets may feel easier to fit into their lifestyle and better suited to their needs, while others may prefer injections or continue seeing strong results with them. What matters most is improving health in a safe and sustainable way, with the right clinical guidance and support to help each person find the treatment that works best for them.”
James O’Loan, CEO and Prescribing Pharmacist at Chemist4U
The science: what the trials show
Oral GLP-1 tablets are not simply traditional ‘diet pills' in a new format. They use the same clinically proven hormonal pathways as existing injectable GLP-1 treatments, and the clinical trial results published so far have shown significant weight loss outcomes.
Clinical trial results at a glance
The clinical trial data around oral GLP-1s is already highly encouraging. Across multiple major studies, oral semaglutide and orforglipron delivered significant weight loss results, reinforcing the idea that these treatments are far more than traditional ‘diet pills’.
Importantly, some patients taking the highest dose of oral semaglutide in trials achieved up to 22% weight loss, bringing results closer to what has previously only been associated with injectable GLP-1 treatments. While injections still currently show the highest overall weight loss outcomes, the data suggests tablets could become a genuinely comparable option for many patients.
What oral GLP-1 tablets can and cannot do
“Clinical trials have shown Wegovy tablets to be highly effective at helping you lose weight. The average weight loss in trials was around 14% over 64 weeks at the 25mg dose. This compared to losing around 21% over 72 weeks for those using a 7.2mg weight loss injection. However, it is important to remember that individual results will vary, with some people losing less weight and others losing more.
Oral GLP-1s are delivering significant weight loss results in clinical trials, with many patients achieving the kind of weight reduction that can meaningfully improve long-term health. For some people, tablets may feel more realistic, manageable and easier to maintain than injections. They are not a lesser option, but a different route into clinically proven weight loss treatment.
Who's ready to switch and who might start?
Existing GLP-1 injection users
For the millions of people already using GLP-1 injections, tablets raise a different question. This is no longer about whether the treatment works, but whether a pill feels easier, more convenient or better suited to long-term life with treatment.
Our research suggests the answer, for many people, is yes.
More than 3 in 4 injection users would consider switching
76.76% of current and previous GLP-1 injection users said they would likely switch to a tablet version if it offered similar effectiveness and cost. And 37.34% said they would be very likely to switch.
Just 6.79% said they would be unlikely to switch.
The findings suggest there is already significant appetite for oral GLP-1s, even among people currently happy with injections.
Younger adults were the most open to switching
Adults aged 25-34 were the most likely to say they would switch, with 87.38% saying they would likely move to a tablet.
Men were also slightly more likely to switch than women (79.75% vs 74.67%).
Younger adults appear especially receptive to the convenience and flexibility tablets may offer.
Some UK cities showed particularly strong interest in switching
People in Liverpool (93.75%), Newcastle (93.75%) and Edinburgh (91.67%) were the most likely to say they would switch from injections to tablets.
Meanwhile, Belfast (57.14%), Glasgow (63.16%) and Southampton (63.16%) were the least likely.
Interest in oral GLP-1s appears to vary considerably across different parts of the UK.
Previous GLP-1 users were especially likely to switch
80.47% of people who had previously used GLP-1 injections said they would likely switch to a tablet option.
For some former users, tablets may feel easier to restart, maintain or fit into everyday life long term.
“What stands out from this research is that people aren’t looking to abandon effective treatment. They are looking for a version of treatment that feels easier to live with. The biggest reasons people gave for switching were convenience, simpler routines and making treatment easier to travel with. That tells us this is not just about avoiding needles but about making long-term weight loss treatment feel more practical in everyday life.”
James O’Loan, CEO and Prescribing Pharmacist at Chemist4U
People who have never used GLP-1s
This is where oral GLP-1s may have the biggest impact. Many clinically eligible UK adults have never pursued treatment, and for a significant number of people, injections are a major reason why.
The findings suggest oral GLP-1s could unlock a significant new patient population, particularly among people who were previously put off by injections.
The generational picture
Age differences in attitudes towards oral GLP-1s
Attitudes towards oral GLP-1 treatments vary significantly by age. Adults under 45 are notably more receptive to the idea of a daily weight loss pill, while older adults remain more cautious, particularly when considering treatment for the first time.
The strongest demand comes from adults aged 25-34, who consistently recorded the highest levels of intent, preference for pills over injections, and willingness to switch from injectable treatment.
What the data suggests
Younger adults appear more comfortable viewing GLP-1s as a mainstream and medically acceptable weight loss option. Adults under 45 consistently showed stronger interest in oral treatments and lower resistance to the idea of prescription weight loss medication overall.
The 25-34 audience stands out as the most receptive age group:
over 54% would actively seek a prescription
nearly 56% find pills more appealing than injections
a striking 87.38% of current injectable users would consider switching to tablets
This suggests oral GLP-1s may particularly resonate with younger working-age adults who value convenience, discretion, and familiarity with daily medication formats.
Meanwhile, adults aged 55+ show the lowest likelihood of pursuing treatment for the first time, with just 20.72% saying they would likely seek a prescription. However, the data also shows that once older adults are already engaged with GLP-1 treatment, resistance to tablets drops sharply:
43.19% say pills are more appealing than injections
64.94% of injectable users would consider switching
This indicates the primary barrier among older adults may not be the pill format itself, but rather initial adoption of GLP-1 treatment in general.
The opportunity
The data points to a major expansion opportunity for oral GLP-1s in the UK market, particularly among younger adults and treatment-hesitant patients.
Among non-users, injection aversion remains a meaningful barrier to uptake. Yet once a pill option is introduced, willingness to engage with treatment rises substantially, especially in the under-45 demographic.
At the same time, existing injectable users across all age groups show exceptionally high openness to switching, with willingness remaining above 64% in every age bracket surveyed.
Taken together, the findings suggest oral GLP-1s could:
unlock entirely new audiences who previously rejected injections
increase treatment uptake among younger adults
improve long-term adherence through familiarity and convenience
create a substantial switching market among existing GLP-1 users
The pill could be the key
Oral GLP-1s could completely change the weight loss market in the UK. The clinical results are strong, demand is already clear, and for many people, a pill simply feels more approachable than an injection ever did.
But tablets are not a shortcut to weight loss. They still require consistency, routine and proper clinical support for the best results. They also come with specific instructions around how and when they need to be taken, and they may not fully replace the role of higher-dose injectable treatments for every patient.
What the pill does offer is choice. And for some people, it could be the thing that finally makes treatment feel realistic and manageable.
At Chemist4U, we believe oral GLP-1s should be introduced with the same level of clinical care, patient education and ongoing support as injectable treatments. If these medications are going to reach the people who could genuinely benefit from them, it is important they are properly understood and prescribed safely.
For millions of people, the needle was the barrier. The pill could remove it.
How we’re adapting
Give people the full picture: oral GLP-1s are exciting, but they are not effortless. People deserve honest information about what these treatments can do, what they cannot do, and what it takes to get good results. Tablets still require consistency, clinical guidance and lifestyle change. The better informed people are from the start, the more likely they are to stick with treatment long term.
Reach the people injections left behind: for many people, the needle was the dealbreaker. Our research shows there is a huge group of adults who may finally consider treatment if it comes in a pill format. That is where the biggest opportunity sits, not just commercially, but from a public health perspective too.
Keep treatment within reach: access matters. If oral GLP-1s are priced too far out of reach, many people simply will not benefit from them. The more affordable and transparent treatment is, the more lives it has the potential to change. At Chemist4U, we believe weight loss treatment should be easier to access, easier to understand, and fairly priced.
What this means for the future of weight loss
The injection is not going anywhere. But the market is about to change.
GLP-1 injections transformed weight loss treatment. They proved that significant, medically supported weight loss is possible at scale, and they changed how millions of people think about obesity treatment in the process.
That is not changing any time soon.
Injectable treatments will continue to play a huge role, particularly for people already established on treatment, people who prefer weekly dosing, and those using higher-dose options to maximise weight loss results.
But oral GLP-1s are not arriving to replace injections entirely. They are arriving to expand the market beyond the people injections could reach.
Because for a huge number of people, the issue was never belief in the science. It was the format.
The needle.
The routine.
The stigma.
The fear of injecting.
The feeling that treatment had become ‘too medical’.
The tablet changes that.
For many people, swallowing a pill feels normal. Familiar. Easier to hide. Easier to fit into everyday life. That psychological shift matters more than many people realise. And our data suggests younger adults understand that immediately.
Younger generations are already moving towards convenience-first healthcare
Adults under 45 consistently showed the strongest interest in oral GLP-1s throughout our research. They were more likely to seek treatment, more likely to prefer pills over injections, and more likely to say they would switch formats if given the option.
That reflects something bigger happening across healthcare.
Younger generations increasingly expect treatment to fit around their lives, not the other way around. They are more comfortable with digital healthcare, online prescribing, app-based support and discreet treatment options delivered directly to their homes.
Convenience is no longer a bonus feature in healthcare. It is becoming the expectation.
Oral GLP-1s fit directly into that. Not because they are ‘easier’, but because they feel more compatible with modern life.
The next generation of weight loss treatment will be built around flexibility
This is unlikely to be the final evolution of GLP-1 treatment. It is probably the beginning of a much broader shift.
Over the next few years, we are likely to see:
More oral treatment options entering the market.
New medications designed to reduce nausea and digestive side effects.
Longer-lasting treatments with simpler dosing schedules.
More personalised prescribing based on patient response and tolerability.
Combination therapies targeting appetite, metabolism and food cravings differently.
Greater integration between medication, nutrition, behaviour change and digital support.
In short, treatment will become more personalised, more flexible and more focused on long-term sustainability.
The future of obesity treatment will not belong to one medication or one format alone. It will belong to the providers who make treatment easier to access, easier to understand and easier to stick with.
This is the start of the next phase
The arrival of oral GLP-1s is not just another product launch. It represents a huge change in who weight loss treatment can reach.
For years, injections opened the door to clinically effective weight loss treatment.
The tablet could open that door much wider.
Not because it changes the science. Because it changes how people feel about starting. And that could be the difference between curiosity and action for millions of people across the UK.
“Obesity is one of the UK’s biggest national health challenges, with co-morbidities such as cancer, cardiovascular disease and diabetes placing a huge strain on the NHS.
“Weight loss injections have proven to be one of the most exciting healthcare developments in recent memory, especially when it comes to the way we discuss obesity.
“However, the introduction of tablets is likely to be revolutionary. With such a large section of society already changing their lives through the use of weight loss injections, new weight loss pills are only set to increase the number of people addressing their own health challenges.”
James O’Loan, CEO and Prescribing Pharmacist at Chemist4U
Methodology
Consumer survey
The research was conducted by Censuswide on behalf of Chemist4U, among a sample of 3,586 UK nationally representative respondents with a minimum of 500 people who have lost weight and 500 people who use weight loss injections. The data was collected between 29.05.2026 and 05.06.2026. Censuswide is a member of the Market Research Society (MRS) and the British Polling Council (BPC), and a signatory of the Global Data Quality Pledge. We adhere to the MRS Code of Conduct and ESOMAR principles.
Clinical data sources
All clinical trial data cited in this report is drawn from peer-reviewed publications in The New England Journal of Medicine and The Lancet, and investor disclosures from Novo Nordisk and Eli Lilly. Full citations are listed in the References section below. Cross-trial efficacy comparisons should be interpreted with caution given differences in study design, population, duration and primary endpoints. Market data on US launch performance is sourced from Novo Nordisk Q1 2026 and Eli Lilly Q1 2026 investor presentations.
Chemist 4 U uses cookies (and other techniques) to enhance your shopping experience.
Read more about our cookie policy, terms and conditions and privacy statement. By continuing on this site and accepting our cookies you agree to the collection of information on this basis by us and by third parties on the platform as well as direct email marketing. Please customise your cookie settings below.
Find out more about our data policies.
